ProCE Banner Activity

Phase Ib Study of Magrolimab Plus Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Slideset Download
Conference Coverage
Combined with azacytidine, the anti-CD47 antibody magrolimab was well tolerated and associated with promising activity in untreated patients with MDS and AML.

Released: June 05, 2020

Expiration: June 04, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono